Today’s blog comes to us from Jonathan Wilson, President of GLOBALHealthPR US Partner and Chair, Spectrum.
The United States Food and Drug Administration (FDA) is rethinking its rules on what kind of information pharma companies can share with physicians regarding off-label use of their products. That’s good news for the practice of medicine.
At the moment, pharma company employees can talk about a drug only in the context of the condition indicated in its FDA-approved label. Anything they say about another, unapproved use of the drug is considered “misbranding” according to federal law, and subjects the company to civil and criminal prosecution. [Read more…] about Scientific Exchange Calls for Some Talk of “Off-Label” Use
